Latest Breaking News On - Silicon therapeutics - Page 1 : comparemela.com

Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC

Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for EGFR-mutant, advanced NSCLC, phase 3 data suggest.

ENLIVEX THERAPEUTICS : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K -September 13, 2023 at 04:45 pm EDT

ENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 26, 2023 Dear Shareholder: We.

Attorneys – Malpractice – Expert evidence | Massachusetts Lawyers Weekly

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.